166 related articles for article (PubMed ID: 38360722)
21. Steroid receptor expression in endometria from women treated with tamoxifen.
Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
[TBL] [Abstract][Full Text] [Related]
22. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
[TBL] [Abstract][Full Text] [Related]
23. Effect of vitamin E on tamoxifen-treated breast cancer cells.
Peralta EA; Viegas ML; Louis S; Engle DL; Dunnington GL
Surgery; 2006 Oct; 140(4):607-14; discussion 614-5. PubMed ID: 17011908
[TBL] [Abstract][Full Text] [Related]
24. POR overexpression induces tamoxifen-resistance in breast cancer through the STAT1/c-Myc pathway.
Chen S; Wu D; Liu Q; Jin F; Yao F; Fang Y
Mol Carcinog; 2023 Feb; 62(2):249-260. PubMed ID: 36321415
[TBL] [Abstract][Full Text] [Related]
25. iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity.
Diaz Bessone MI; Simón-Gracia L; Scodeller P; Ramirez MLA; Lago Huvelle MA; Soler-Illia GJAA; Simian M
J Nanobiotechnology; 2019 Dec; 17(1):120. PubMed ID: 31812165
[TBL] [Abstract][Full Text] [Related]
26. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
27. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
28. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.
Dalenc F; Giamarchi C; Petit M; Poirot M; Favre G; Faye JC
Breast Cancer Res; 2005; 7(6):R1159-67. PubMed ID: 16457696
[TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
30. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells.
Perry RR; Kang Y; Greaves BR
Br J Cancer; 1995 Dec; 72(6):1441-6. PubMed ID: 8519657
[TBL] [Abstract][Full Text] [Related]
31. FE65 defines the efficacy of tamoxifen treatment via osteopontin expression in estrogen receptor-positive breast cancer.
Xu J; Iwabuchi E; Miki Y; Kanai A; Takagi K; Suzuki T; Ishida T; Sasano H
Pathol Res Pract; 2022 Jun; 234():153898. PubMed ID: 35447603
[TBL] [Abstract][Full Text] [Related]
32. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
33. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
34. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
Nomura Y; Shirouzu M; Takayama T
Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
[TBL] [Abstract][Full Text] [Related]
35. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
[TBL] [Abstract][Full Text] [Related]
36. EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer.
Xie Y; Han X; Yu J; Yuan M; Yan Y; Qin J; Lan L; Wang Y
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18103-18117. PubMed ID: 37999751
[TBL] [Abstract][Full Text] [Related]
37. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
38. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
39. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
40. Effects of tamoxifen on human squamous cell carcinoma lines of the head and neck.
Hoffmann TK; Bojar H; Eckel J; van Lierop A; Balz V; Friebe-Hoffmann U; Hauser U; Bier H
Anticancer Drugs; 2002 Jun; 13(5):521-31. PubMed ID: 12045464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
